DFTX

Definium is a late-stage clinical biopharma with zero revenue across all five reported fiscal years and an accelerating cash burn — FY2025 net loss widened 69.1% to -$184M and operating cash outflow worsened 66.3% to -$132M, driven by an 80.2% jump in R&D to $118M as the company funded three concurrent Phase 3 trials (Voyage, Panorama, Emerge) for DT120 ODT, its lysergide-derived candidate for GAD and MDD. Accumulated deficit has ballooned to -$583M and share count grew 32.3% YoY to 99.7M, confirming the company funds itself by serially diluting shareholders.

The filing language makes this a textbook event-driven binary. Management explicitly flags three pivotal readouts inside the next ~6 months: Emerge (MDD Part A) in late Q2 2026, Voyage (GAD Part A) in early Q3 2026, and Panorama (GAD Part A) in H2 2026. The Phase 2b GAD result hit its HAM-A primary endpoint with FDA Breakthrough Designation and JAMA publication — a real scientific signal — but psychedelic Phase 3 trials in psychiatry have a poor track record of replicating Phase 2 effect sizes against placebo, and the entire enterprise value hangs on these three reads. Today's +16.45% move into a known catalyst window only sharpens the asymmetry against new buyers.